Biologic Response of Colorectal Cancer Xenograft Tumors to Sequential Treatment with Panitumumab and Bevacizumab

Recent studies in RAS wild-type (WT) metastatic colorectal cancer (mCRC) suggest that the survival benefits of therapy using anti-epidermal growth factor receptor (anti-EGFR) and anti-vascular endothelial growth factor (anti-VEGF) antibodies combined with chemotherapy are maximized when the anti-EGF...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neoplasia
Autors principals: Taniguchi, Hiroya, Baba, Yuji, Sagiya, Yoji, Gotou, Masamitsu, Nakamura, Kazuhide, Sawada, Hiroshi, Yamanaka, Kazunori, Sakakibara, Yukiko, Mori, Ikuo, Hikichi, Yukiko, Soeda, Junpei, Baba, Hideo
Format: Artigo
Idioma:Inglês
Publicat: Neoplasia Press 2018
Matèries:
Original article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6030230/
https://ncbi.nlm.nih.gov/pubmed/29802988
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.neo.2018.04.006
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars